Tecfidera’s (dimethyl fumarate) usual dosage for MS and CIS is 120 mg twice per day for 7 days, and then 240 mg twice per day. Tecfidera treats the following conditions: relapsing-remitting multiple ...

Biogen’s contingency plan to keep Tecfidera generics at bay has fallen flat. After a U.S. appeals court in November declined to resurrect a key patent on Biogen’s multiple sclerosis (MS) blockbuster ...

The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...

The FDA has approved a new multiple sclerosis drug made by Biogen Idec Inc. that's viewed as the best in a new wave of treatments for the disease. The drug, Tecfidera, is taken orally and works by ...

Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

As Biogen’s relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive ...

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...

Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...

Biogen Inc’s TECFIDERA has received approval from the National Medical Products Administration (NMPA) in China for treating relapsing multiple sclerosis (MS). This approval expands Biogen’s (BIIB) ...